Skip to main content

Advertisement

SpringerLink
Log in

Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Tumor necrosis factor alpha (TNF-alpha) plays an important role in the pathogenesis of chronic inflammatory diseases, i.e., rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis (UC). Anti-TNF-alpha strategies are successfully used in their treatment. However, their effect on heart function is still uncertain. The objectives of the study were to examine the acute and long-term effect of infliximab on the heart morphology and function in patients with chronic inflammatory disorders. Thirty-one patients (21 men and 10 women) were included. Ten percent of them were diagnosed with RA, 22.5 % with AS, 22.5 % with CD, and 45 % with UC, respectively. N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) was measured before and immediately after infliximab administration at the beginning of the study and in the sixth and 12th months. Echocardiography was performed at baseline and in the sixth and 12th months. There was a significant increase in NT-proBNP after the first infliximab infusion (88.40 ± 14.09 vs. 95.24 ± 14.28 pg/ml, p = 0.0046) and similar response was detected after each infusion in the sixth and 12th months. Plasma NT-proBNP slightly but not significantly decreased (88.40 ± 14.09 vs. 81.74 ± 23.14 pg/ml, p = 0.583, and 88.40 ± 14.09 vs. 56.83 ± 17.77 pg/ml, p = 0.0576, in the sixth and 12th months, respectively). There were no significant changes in echocardiographic structural and functional parameters of the left ventricle during follow-up. Plasma NT-proBNP mildly but significantly increases immediately after infliximab infusion. However, long-term infliximab administration does not deteriorate both cardiac morphology and function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732

    Article  PubMed  Google Scholar 

  2. Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4(5):R5

    Article  PubMed  Google Scholar 

  3. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloy JA et al (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57(1):125–132

    Article  PubMed  CAS  Google Scholar 

  4. Haapamäki J, Roine RP, Turunen U, Färkkilä MA, Arkkila PE (2011) Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 5(1):41–47

    Article  PubMed  Google Scholar 

  5. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214(2):149–160

    Article  PubMed  CAS  Google Scholar 

  6. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Eng J Med 343(22):1594–1602

    Article  CAS  Google Scholar 

  7. Braun J, McHugh N, Singh A, Wajdula JS, Sato R (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 46(6):999–1004

    Article  PubMed  CAS  Google Scholar 

  8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549

    Article  PubMed  CAS  Google Scholar 

  9. Caviglia R, Boskoski I, Cicala M (2008) Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 5:617–632

    Article  Google Scholar 

  10. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133–3140

    Article  PubMed  CAS  Google Scholar 

  11. Anker SD, Coats AJS (2002) How to RECOVER FROM RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86:123–130

    Article  PubMed  Google Scholar 

  12. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM et al (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:1044–1047

    Article  PubMed  CAS  Google Scholar 

  13. Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116(5):305–311

    Article  PubMed  Google Scholar 

  14. Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D et al (2007) Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonists. Rheumatology 46:1688–1693

    Article  PubMed  CAS  Google Scholar 

  15. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S et al (2008) Does tumor necrosis factor-α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667–677

    Article  PubMed  CAS  Google Scholar 

  16. Cole J, Busti A, Kazi S (2007) The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 27:369–373

    Article  PubMed  CAS  Google Scholar 

  17. Peters MJ, Welsh P, MsInnes IB, Wolbink G, Dijkmans BA, Satttar N et al (2010) Tumor necrosis factor alpha blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 69:1281–1285

    Article  PubMed  CAS  Google Scholar 

  18. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1309

    Article  PubMed  Google Scholar 

  19. Brunner F, Kunz A, Weber U, Kissling R (2006) Ankylosing pondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in normal population? Clin Rheumatol 25(1):24–29

    Article  PubMed  Google Scholar 

  20. Bragagni G, Brogna R, Franceschetti P, Zoli G (2007) Cardiac involvement in Crohn's disease: echocardiographic study. J Gastroenterol Hepatol 22(1):18–22

    Article  PubMed  Google Scholar 

  21. Provan SA, Semb AG, Hisdal J, Stranden E, Agewall S, Dagfinrud H et al (2011) Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 70:812–817

    Article  PubMed  Google Scholar 

  22. Davis JM 3rd, Knutson KL, Straubauch MA, Crowson CS, Therneau TM, Wettstein PJ et al (2011) A singature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum 63:1497–1506

    Article  PubMed  CAS  Google Scholar 

  23. Torre-Amione G, Bozkurt B, Deswal A, Mann DL (1999) An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 14:206–210

    Article  PubMed  CAS  Google Scholar 

  24. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN (2002) Identification of novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 34:509–518

    Article  PubMed  CAS  Google Scholar 

  25. Espiner EA, Richards AM, Yandle TG, Nicholls MG (1995) Natriuretic hormones. Endocrinol Metab Clin N Am 24:481–509

    CAS  Google Scholar 

  26. Niessner A, Ziegler S, Slany J, Billensteiner E, Woloszczuk W, Geyer G (2003) Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids? Eur J Endocrinol 149:555–559

    Article  PubMed  CAS  Google Scholar 

  27. Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807–811

    PubMed  Google Scholar 

  28. Singh M, Diwan MM, Patel KCR (2009) A rare case of supraventricular tachycardia induced by infliximab: a case report. Cases J 2:147–150

    Article  PubMed  Google Scholar 

  29. Sote Y, Green S, Maddison P (2008) Complete heart block after infliximab therapy. Rheumatology 47:227–228

    Article  PubMed  CAS  Google Scholar 

  30. Bragagni G, Lari F, Magenta G, Brogna R, Zoli G (2010) Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies. Recenti Prog Med 101:289–292

    PubMed  Google Scholar 

  31. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16(2):CD008794

    Google Scholar 

Download references

Acknowledgments

The study was funded by the Ministry of Health, Slovak Republic (2007/4-UPJS-01).

Disclosures

None

Author information

Authors and Affiliations

  1. 1st Department of Internal Medicine, Medical Faculty, P.J. Šafárik University, Trieda SNP 1, Košice, Slovakia

    Ľubomír Tomáš, Ivica Lazúrová, Lýdia Pundová, Mária Oetterová & Mária Zakuciová

  2. Institute of Experimental Medicine, Medical Faculty, P.J. Šafárik University, Košice, Slovakia

    Darina Petrášová

  3. Eastslovakian Institute of Cardiology, Košice, Slovakia

    Martin Studenčan

Authors
  1. Ľubomír Tomáš
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivica Lazúrová
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lýdia Pundová
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mária Oetterová
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mária Zakuciová
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Darina Petrášová
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martin Studenčan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivica Lazúrová.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomáš, Ľ., Lazúrová, I., Pundová, L. et al. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol 32, 61–66 (2013). https://doi.org/10.1007/s10067-012-2091-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2091-4

Keywords

Search

Navigation